tetano
Editor, Senior Moderator
BMC Infect Dis
. 2025 Jul 1;25(1):840.
doi: 10.1186/s12879-025-11195-9. Real-world effectiveness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China: a retrospective cohort study
Chuntao Li[SUP] #[/SUP][SUP] 1 [/SUP], Qingzhao Cheng[SUP] #[/SUP][SUP] 1 [/SUP], Ying Chen[SUP] 2 [/SUP], Ling Liu[SUP] 1 [/SUP], Dajin Liu[SUP] 3 [/SUP], Jiaqiang Zhang[SUP] 1 [/SUP], Zehua Liao[SUP] 1 [/SUP], Yaling Xiang[SUP] 1 [/SUP], Jinbiao Zhou[SUP] 1 [/SUP], Keke Liao[SUP] 1 [/SUP], Yandi Su[SUP] 1 [/SUP], Xuemei Zhang[SUP] 1 [/SUP], Jiashu Li[SUP] 1 [/SUP], Yuping Zhao[SUP] 1 [/SUP], Yue Yang[SUP] 1 [/SUP], Jianqing Zhang[SUP] 4 [/SUP], Long Yang[SUP] 5 [/SUP]
Affiliations
Objective: This study aims to assess the comparative clinical effectiveness of the 3-chymotrypsin-like protease (3CLpro) inhibitors simnotrelvir-ritonavir and nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China.
Methods: The retrospective analysis of data from adult hospitalized patients with COVID-19 treated with either simnotrelvir-ritonavir or nirmatrelvir-ritonavir as antiviral treatment strategies will be conducted to determine any differences in clinical outcomes between the two drugs.
Results: This study involved a total of 585 participants, with 264 in the simnotrelvir group and 321 in the nirmatrelvir group. Following propensity score matching, there were 186 individuals in each group. There was no statistically significant difference in the cumulative risk of the composite disease progression, all-cause death, and respiratory support at 28 days following initiation of drug exposure between the two groups (p > 0.05). However, the simnotrelvir group exhibited more cases of clinical improvement compared to the nirmatrelvir group (33.602 events per 1000 person-days vs. 30.913 events per 1000 person-days), with a better cumulative incidence in the simnotrelvir group (p < 0.05). The multivariate Cox regression analysis revealed that non-severe COVID-19 (HR 0.630, 95% CI 0.496-0.801; p < 0.001), lower C-reactive protein (CRP) levels (HR 0.993, 95% CI 0.990-0.997; p < 0.001), and treatment with simnotrelvir-ritonavir (HR 1.395, 95% CI 1.118-1.741; p = 0.003) were independently associated with a higher likelihood of clinical improvement.
Conclusion: This study illustrated that both simnotrelvir-ritonavir and nirmatrelvir-ritonavir exhibited similar effectiveness in reducing the incidence of composite disease progression, all-cause death, and the need for respiratory support amidst the real-world outbreak of the omicron VOC in China. Furthermore, simnotrelvir-ritonavir was found to be more favorable in enhancing the rate of clinical improvement in COVID-19 hospitalized patients, suggesting its potential clinical effectiveness against the disease.
Keywords: All-cause death; COVID‐19; Clinical improvement; Composite disease progression; Nirmatrelvir-ritonavir; Simnotrelvir-ritonavir.
. 2025 Jul 1;25(1):840.
doi: 10.1186/s12879-025-11195-9. Real-world effectiveness of simnotrelvir-ritonavir versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China: a retrospective cohort study
Chuntao Li[SUP] #[/SUP][SUP] 1 [/SUP], Qingzhao Cheng[SUP] #[/SUP][SUP] 1 [/SUP], Ying Chen[SUP] 2 [/SUP], Ling Liu[SUP] 1 [/SUP], Dajin Liu[SUP] 3 [/SUP], Jiaqiang Zhang[SUP] 1 [/SUP], Zehua Liao[SUP] 1 [/SUP], Yaling Xiang[SUP] 1 [/SUP], Jinbiao Zhou[SUP] 1 [/SUP], Keke Liao[SUP] 1 [/SUP], Yandi Su[SUP] 1 [/SUP], Xuemei Zhang[SUP] 1 [/SUP], Jiashu Li[SUP] 1 [/SUP], Yuping Zhao[SUP] 1 [/SUP], Yue Yang[SUP] 1 [/SUP], Jianqing Zhang[SUP] 4 [/SUP], Long Yang[SUP] 5 [/SUP]
Affiliations
- PMID: 40597719
- PMCID: PMC12211424
- DOI: 10.1186/s12879-025-11195-9
Objective: This study aims to assess the comparative clinical effectiveness of the 3-chymotrypsin-like protease (3CLpro) inhibitors simnotrelvir-ritonavir and nirmatrelvir-ritonavir in hospitalized patients with COVID-19 during the omicron wave in China.
Methods: The retrospective analysis of data from adult hospitalized patients with COVID-19 treated with either simnotrelvir-ritonavir or nirmatrelvir-ritonavir as antiviral treatment strategies will be conducted to determine any differences in clinical outcomes between the two drugs.
Results: This study involved a total of 585 participants, with 264 in the simnotrelvir group and 321 in the nirmatrelvir group. Following propensity score matching, there were 186 individuals in each group. There was no statistically significant difference in the cumulative risk of the composite disease progression, all-cause death, and respiratory support at 28 days following initiation of drug exposure between the two groups (p > 0.05). However, the simnotrelvir group exhibited more cases of clinical improvement compared to the nirmatrelvir group (33.602 events per 1000 person-days vs. 30.913 events per 1000 person-days), with a better cumulative incidence in the simnotrelvir group (p < 0.05). The multivariate Cox regression analysis revealed that non-severe COVID-19 (HR 0.630, 95% CI 0.496-0.801; p < 0.001), lower C-reactive protein (CRP) levels (HR 0.993, 95% CI 0.990-0.997; p < 0.001), and treatment with simnotrelvir-ritonavir (HR 1.395, 95% CI 1.118-1.741; p = 0.003) were independently associated with a higher likelihood of clinical improvement.
Conclusion: This study illustrated that both simnotrelvir-ritonavir and nirmatrelvir-ritonavir exhibited similar effectiveness in reducing the incidence of composite disease progression, all-cause death, and the need for respiratory support amidst the real-world outbreak of the omicron VOC in China. Furthermore, simnotrelvir-ritonavir was found to be more favorable in enhancing the rate of clinical improvement in COVID-19 hospitalized patients, suggesting its potential clinical effectiveness against the disease.
Keywords: All-cause death; COVID‐19; Clinical improvement; Composite disease progression; Nirmatrelvir-ritonavir; Simnotrelvir-ritonavir.